Pfizer says Lipitor significantly reduces risk of cardio events vs Simvastatin |
|
|
|
Published
:
Fri, 02 Mar 2007 19:20
|
LONDON (AFX) - Pharmaceutical giant Pfizer Inc said that a retrospective analysis of a large U.S. managed care database showed that patients who took Pfizer's cholesterol-lowering medicine Lipitor had a significant 14 pct reduction in the risk of cardiovascular events, including heart attacks and strokes, compared with patients who took simvastatin.To replicate real-world physician behavior, Pfizer said the study was designed to adjust for expected differences of Lipitor and simvastatin LDL lowering based on dose.Lipitor patients achieved a significant additional 14 pct reduction in the risk of cardiovascular events compared with patients taking simvastatin, even after the dose adjustments, fizer said.newsdesk@afxnews.comrwCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
Print this Story
Pfizer says intensive Lipitor therapy cuts hospitalizations for heart failure 